Novo Nordisk Discontinues Porcine Insulin in the US
Novo Nordisk has discontinued porcine insulin in the United States as of February 7, 2000. Health care providers (physicians, diabetes educators, pharmacists) were notified by an extensive direct mail campaign.
The Novo Nordisk products that have been discontinued are Regular Purified Pork R, NPH Purified Pork N and Lente Purified Pork L. The insulin will be made available until July, or until current supplies are exhausted, whichever comes first, to allow for a comfortable transition to a suitable insulin alternative. Lente is the only exception. The supply of Lente Purified Pork Insulin expires at the end of February and will not be replenished.
Since the introduction of human insulin, the medical community's demand for animal insulin has diminished dramatically. Currently in the United States, less than 2 percent of insulin requiring patients use animal derived insulin.
Alternatives to using Novo Nordisk porcine insulin include human insulin, which is structurally identical to the insulin produced naturally by the body, or purified pork R, N and L, which are available from another manufacturer. Any change in insulin therapy should be made cautiously and under medical supervision, so patients currently using our products should contact their physicians to talk about appropriate alternatives.
If anyone has any questions they can talk with someone in the Novo Nordisk medical department call center at 1-800-727-6500, or via e-mail at NNPI4Answers@nnpi.com.
Posted 5 March 2000
Source: Novo Nordisk
Last Updated: Thursday February 27, 2014 19:28:21
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.
This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents.
© Children with Diabetes, Inc. 1995-2016. Comments and Feedback.